GLP-1 对 COVID-19 患者的抗炎作用。
Anti-inflammatory effects of GLP-1 in patients with COVID-19.
机构信息
School Of Medicine, Tehran University Of Medical Sciences, Tehran, Iran.
Students' Scientific Research Center, Tehran University Of Medical Sciences, Tehran, Iran.
出版信息
Expert Rev Anti Infect Ther. 2022 Mar;20(3):373-381. doi: 10.1080/14787210.2021.1964955. Epub 2021 Aug 12.
Abstract
INTRODUCTION
Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is awell-known glucose-lowering agent with anti-inflammatory effects.
AREAS COVERED
Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1 RA, SARS-CoV-2, COVID-19, inflammation, in April2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications are discussed. However, GLP-1 is degraded by DPP-4 with aplasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings.
EXPERT OPINION
Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.
摘要
简介
了解新型冠状病毒病 2019（COVID-19）的发病机制和危险因素是必要的。由于炎症途径在 COVID-19 患者发病机制中的重要性，评估抗炎药物的效果很重要。胰高血糖素样肽 1 受体激动剂（GLP-1RA）是一种众所周知的具有抗炎作用的降糖药物。
涵盖领域
资源取自 2021 年 4 月的 PubMed 数据库，使用的关键词有胰高血糖素样肽-1、GLP-1RA、严重急性呼吸综合征冠状病毒 2、COVID-19、炎症。在这篇综述中，讨论了 GLP-1RA 对减轻炎症和改变 COVID-19 严重并发症危险因素的作用。然而，GLP-1 会被二肽基肽酶 4（DPP-4）降解，血浆半衰期约为 2-5 分钟，这使得在临床环境中很难测量 GLP-1 血浆水平。
专家意见
由于目前尚无针对 COVID-19 的明确治疗方法，因此确定有希望的靶点来设计和/或重新利用有效的药物是必要的。
相似文献
1
Anti-inflammatory effects of GLP-1 in patients with COVID-19.
Expert Rev Anti Infect Ther. 2022 Mar;20(3):373-381. doi: 10.1080/14787210.2021.1964955. Epub 2021 Aug 12.
2
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clin Obes. 2021 Apr;11(2):e12439. doi: 10.1111/cob.12439. Epub 2021 Jan 10.
3
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. doi: 10.1080/14740338.2021.1970744. Epub 2021 Aug 25.
4
Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
Diabetes Ther. 2023 Dec;14(12):2127-2142. doi: 10.1007/s13300-023-01472-8. Epub 2023 Oct 6.
5
Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.
Diabetes Res Clin Pract. 2021 Sep;179:109031. doi: 10.1016/j.diabres.2021.109031. Epub 2021 Aug 28.
6
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.
Ther Innov Regul Sci. 2024 Jul;58(4):773-787. doi: 10.1007/s43441-024-00633-6. Epub 2024 Apr 29.
7
Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
J Diabetes Investig. 2022 Jun;13(6):965-974. doi: 10.1111/jdi.13749. Epub 2022 Feb 8.
8
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
Diabetes Obes Metab. 2022 May;24(5):788-805. doi: 10.1111/dom.14640. Epub 2022 Jan 21.
9
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
10
Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension.
Med Hypotheses. 2022 Jan;158:110739. doi: 10.1016/j.mehy.2021.110739. Epub 2021 Dec 9.
引用本文的文献
1
Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients.
Crit Care Sci. 2024 Aug 5;36:e20240028en. doi: 10.62675/2965-2774.20240028-en. eCollection 2024.
2
Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes.
Biomedicines. 2024 Feb 22;12(3):488. doi: 10.3390/biomedicines12030488.
3
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
Ther Adv Endocrinol Metab. 2024 Jan 27;15:20420188231222367. doi: 10.1177/20420188231222367. eCollection 2024.
4
Inulin Inhibits the Inflammatory Response through Modulating Enteric Glial Cell Function in Type 2 Diabetic Mellitus Mice by Reshaping Intestinal Flora.
ACS Omega. 2023 Sep 28;8(40):36729-36743. doi: 10.1021/acsomega.3c03055. eCollection 2023 Oct 10.
5
Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
Diabetes Ther. 2023 Dec;14(12):2127-2142. doi: 10.1007/s13300-023-01472-8. Epub 2023 Oct 6.
6
Maintenance of Enteral ACE2 Prevents Diabetic Retinopathy in Type 1 Diabetes.
Circ Res. 2023 Jan 6;132(1):e1-e21. doi: 10.1161/CIRCRESAHA.122.322003. Epub 2022 Nov 30.
7
COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.
Front Endocrinol (Lausanne). 2022 Aug 19;13:974540. doi: 10.3389/fendo.2022.974540. eCollection 2022.
8
Peptide-Based Vaccines and Therapeutics for COVID-19.
Int J Pept Res Ther. 2022;28(3):94. doi: 10.1007/s10989-022-10397-y. Epub 2022 Apr 19.
9
Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis.
Healthcare (Basel). 2022 Mar 30;10(4):645. doi: 10.3390/healthcare10040645.
10
Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.
Int J Clin Pract. 2021 Nov;75(11):e14833. doi: 10.1111/ijcp.14833. Epub 2021 Sep 21.
本文引用的文献
1
Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic.
Rev Clin Esp (Barc). 2022 Apr;222(4):229-232. doi: 10.1016/j.rceng.2021.04.002. Epub 2021 Jun 5.
2
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.
Diabetes Care. 2021 Jul;44(7):1564-1572. doi: 10.2337/dc21-0065. Epub 2021 Jun 16.
3
COVID-19 severity and obesity: are MAIT cells a factor?
Lancet Respir Med. 2021 May;9(5):445-447. doi: 10.1016/S2213-2600(21)00140-5. Epub 2021 Apr 9.
4
Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women.
Nutrients. 2021 Mar 6;13(3):865. doi: 10.3390/nu13030865.
5
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
Lancet Diabetes Endocrinol. 2021 May;9(5):293-303. doi: 10.1016/S2213-8587(21)00050-4. Epub 2021 Mar 30.
6
Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
Lancet Diabetes Endocrinol. 2021 May;9(5):251-252. doi: 10.1016/S2213-8587(21)00059-0. Epub 2021 Mar 30.
7
COVID-19 and Oxidative Stress.
Biochemistry (Mosc). 2020 Dec;85(12):1543-1553. doi: 10.1134/S0006297920120068.
8
Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?
Gut Pathog. 2021 Feb 25;13(1):14. doi: 10.1186/s13099-021-00407-7.
9
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas.
Nat Metab. 2021 Feb;3(2):149-165. doi: 10.1038/s42255-021-00347-1. Epub 2021 Feb 3.
10
Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.
Respir Res. 2021 Jan 18;22(1):20. doi: 10.1186/s12931-020-01603-w.
Zotero 插件